| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Department of Pathology, Baylor College of Medicine, and Houston Department of Veterans Affairs Medical Center, Houston, Texas
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Prostate growth is controlled by a variety of polypeptide growth factors, including members of the fibroblast growth factor (FGF) gene family.2 FGF2, FGF7, and FGF9 are all present in high concentrations in normal human prostate.3-6 FGF2 is a potent growth factor for prostatic stromal cells.4,6,7 In addition it can stimulate proliferation of primary prostatic epithelial cells in culture.5,6 Thus FGF2 can act as both a paracrine growth factor for prostatic epithelial cells and as an autocrine growth factor for prostatic stromal cells.
The concentration of both FGF74 and FGF23,4 are significantly increased in hyperplastic prostate in comparison to normal peripheral and transition zone tissue. FGF2 is a potent mitogen for prostatic stromal cells and quantitative analysis of cellular proliferation by Ki67 immunohistochemistry of frozen sections of the tissue taken before protein extraction revealed a correlation between increased FGF2 tissue concentration and increased proliferation of stromal cells in BPH tissue,4 consistent with a key role for this growth factor in driving the abnormal stromal proliferation in BPH.
Given that FGF2 protein is increased in BPH and that this overexpression has functional consequences for the proliferation of prostatic stromal cells, we sought to determine what factors control FGF2 expression in the human prostate. We report here that interleukin (IL)-8 is produced by prostatic epithelial cells and can act as a paracrine inducer of FGF2 production by prostatic stromal cells in vitro. In addition, we have found that IL-8 is present in substantial quantities in human prostate in vivo and that IL-8 concentration is elevated in BPH tissue. Thus stromal proliferation in BPH is controlled, at least in part, by IL-8 secreted by prostatic epithelial cells. This may ultimately lead to increased tissue mass in the prostatic transition zone, which is critical in the pathogenesis of BPH.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Samples of the benign peripheral zone of the prostate and normal or hyperplastic transition zone were taken from radical prostatectomies. Tissues were received fresh and portions snap-frozen in liquid nitrogen or used to establish primary cell cultures (see below). The frozen tissues were then analyzed by frozen section to confirm the absence of carcinoma or high-grade prostatic intraepithelial neoplasia. Samples of hyperplastic transition zone were also harvested from suprapubic prostatectomies performed for the treatment of severe BPH.
Cell Culture, Production of Epithelial-Conditioned Medium, and Assay for FGF2 Induction
Primary epithelial and stromal cell cultures were established using prostatic tissue samples from the peripheral zone as described previously.8 To prepare conditioned medium, primary epithelial cells were plated in 10-cm tissue culture dishes. When the cells were subconfluent epithelial growth medium was replaced with 8 ml of MCDB 153 medium containing insulin, transferrin, selenium, bovine serum albumin, and oleic acid (1% ITS+2; Sigma Chemical Co., St. Louis, MO). Conditioned medium was collected after 72 hours. The epithelial cells tolerated this treatment well and appeared healthy after this period. To assay for FGF2 induction 2 x 106 primary stromal cells were plated in 10-cm tissue culture dishes. The following day cells were placed in 4.5 ml of RPMI 1640 with 1% ITS+2. Cells were then treated with either 500 µl of epithelial conditioned medium or MCDB 153 with 1% ITS+2 as control. At intervals aliquots of medium were removed for analysis of FGF2 content by enzyme-linked immunosorbent assay (ELISA) as described below. Cell extracts were also prepared by lysing cells in buffer containing 20 mmol/L Tris, pH 8.2, 2 mmol/L ethylenediaminetetraacetic acid, 1 mmol/L dithiothreitol, 0.1% Nonidet P-40, 250 mmol/L NaCl, 2 µg/ml aprotinin, 2 µg/ml leupeptin, 2 µg/ml benzamidine, and 1 mmol/L phenylmethyl sulfonyl fluoride. The cell lysate was cleared by centrifugation for 10 minutes in a microcentrifuge.
To determine whether IL-8 could induce FGF2 production, stromal cultures were plated as above and treated with either 167 pg/ml of recombinant IL-8 (R&D Systems, Minneapolis, MN) in RPMI 1640 with 1% ITS+2 and FGF2 content determined by ELISA on aliquots of medium removed at 6-hour intervals. To block IL-8 activity, 800 µl of conditioned medium was preincubated with 1.0 µg of neutralizing anti-IL-8 monoclonal antibody (mAb B208, R&D Systems) for 1 hour at 37°C. Control antibody was monoclonal anti-ß actin antibody (A5441, Sigma Chemical Co.). A second approach to blocking IL-8 activity was to use lipopolysaccharide (LPS) treatment, which decreases IL-8 receptor mRNA by transcriptional9 and posttranscriptional mechanisms.9,10 Before addition of conditioned medium, stromal cultures were pretreated with LPS (Sigma Chemical Co.) at 10 ng/ml in growth medium for 24 hours. For both blocking experiments FGF2 concentration was determined by ELISA of stromal medium removed after 6 hours of treatment with conditioned medium.
Immunohistochemistry
Frozen tissue sections were fixed in acetone for 10 minutes and stored at -80°C. All sections were treated with Autoblocker (R&D Systems) to inhibit endogenous peroxidase and avidin/biotin (Vector Laboratories, Burlingame, CA) to block endogenous biotin. The sections were incubated with 100 ng/ml of anti-FGF2 mouse monoclonal antibody (GF22; Oncogene Research Products, Cambridge, MA) or rabbit polyclonal anti-IL-8 antibody (SC 7922; Santa Cruz Biotechnology, Santa Cruz, CA) at 4°C for 12 hours. After liberal washing with phosphate-buffered saline (PBS), pH 7.4, sections were then incubated with appropriate biotinylated secondary antibody at 7.5 µg/ml for 45 minutes at room temperature (Vector Laboratories). Sections were then washed with PBS containing 0.1% Tween 20 and incubated with avidin-biotin complex (Vectastain Elite, Vector Laboratories) for 15 minutes. The antigen-antibody reaction was demonstrated using diaminobenzidine as substrate and the sections then counterstained with hematoxylin.
Enumeration of FGF2-Expressing Cells
To determine the number of FGF2 cells that were located near epithelial acini or in stromal areas without adjacent epithelium a point-counting protocol was used as described previously.11 A total of 10 periacinar and stromal fields were counted and the result individually summed for each slide. A total of six slides each from the normal peripheral zone, normal transition zone, and hyperplastic transition zone were examined.
ELISA
Cell extracts were prepared from snap-frozen tissues for ELISA as described previously.6 Protein content of tissue and cell extracts was determined by the method of Bradford.6 Determination of the FGF2 and IL-8 concentration in the media and cell extracts was performed by ELISA based on a quantitative sandwich immunoassay technique. For quantification of IL-8, 96-well enzyme immunoassay plates (Nunc, Rochester, NY) were coated with 0.5 µg/ml of capture antibody (mAb 208, R&D Systems) for 24 hours at room temperature. The plates were washed with PBS with 0.05% Tween 20 (wash buffer) to remove unbound antibodies. Plates were then blocked with PBS containing 1% bovine serum albumin, 5% sucrose, and 0.05% sodium azide for 2 hours at room temperature. This was followed by the addition of 10 to 100 µl of culture medium or tissue extract per well in a total final volume of 100 µl and incubation at room temperature for 2.5 hours. Recombinant IL-8 (R&D Systems) was used as standard. After multiple washes with wash buffer, the plates were incubated with biotinylated anti-human IL-8 antibody (BAF 208, R&D Systems) at 100 ng/ml for 2 hours at room temperature. Plates were washed liberally with wash buffer and 100 µl of diluted peroxidase-conjugated streptavidin (1:4000; Zymed Laboratories, San Francisco, CA) was aliquoted per well and incubated for 30 minutes at room temperature. The plates were then washed with wash buffer and incubated with 100 µl per well of substrate consisting of a 1:1 mixture of peroxidase solution and tetramethyl benzidine substrate (KPL, Gaithersburg, MD) for 15 minutes at room temperature. The enzymatic activity was stopped with 5 N sulfuric acid and optical density determined at 450 nm in a microplate reader. FGF2 ELISA was quantified by using a FGF2 ELISA kit from R&D Systems according to the manufacturer’s instructions. The IL-8 ELISA was linear from 60 to 2000 pg/ml whereas the FGF2 ELISA was linear from 1 to 64 pg/ml.
Northern Blotting and Quantitative Reverse Transcriptase-Polymerase Chain Reaction Analysis
Total RNA was extracted using Trizol reagent as per the manufacturer’s instructions (Life Technologies, Inc., Gaithersburg, MD). For Northern blotting, RNA (10 µg) was electrophoresed through 1.2% agarose gel at 50°C. The samples were then transferred to nylon membranes overnight, fixed by ultraviolet cross-linking, and hybridized overnight in Hybrisol I (Oncor, Gaithersburg, MD) at 42°C with 1 x 106 cpm/ml of 32P-labeled FGF2 cDNA probe prepared as described previously.8 An equal amount of radiolabeled glyceraldehyde-3'-phosphate dehydrogenase probe (Clontech, Palo Alto, CA) was added 6 hours later. Filters were washed at 42°C for 20 minutes in 2x standard saline citrate containing 0.2% sodium dodecyl sulfate, followed by washing at 65°C for 40 minutes in 0.2% standard saline citrate containing 0.1% sodium dodecyl sulfate. The filters were exposed to Kodak XAR5 film (Eastman-Kodak, Rochester, NY) for 12 to 24 hours. Bands on the autoradiograms were quantified by densitometry using the Imagequant program on a Molecular Dynamics PhosphorImager. Reverse transcription and polymerase chain reaction with FGF2-specific primers was performed as described previously8 except that reactions were performed for either 20 or 30 cycles. In addition, primers for ß2 microglobulin were added as internal controls. The primer sequences for ß2 microglobulin were 5'-ACCCCCACTGAAAAAGATGA (forward) and 5'-ATCTTCAAACCTCCATGATG (reverse). After the reaction was complete, 20 µl was analyzed by electrophoresis in a 2.5% agarose gel and stained with ethidium bromide.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
To determine the localization of the increased FGF2 in BPH we
examined tissue sections from normal peripheral and transition zone and
BPH tissues after immunohistochemistry with anti-FGF2 monoclonal
antibody. FGF2 was expressed in stromal cells with fibroblastic
morphology. In these sections we noted a definite tendency for the
FGF2-positive cells to be located near the epithelial acini. Examples
of such concentrations of FGF2-positive cells near epithelial acini are
shown in Figure 1
as well as a control
photomicrograph of an adjacent stromal area. It should be noted that
this distribution was not uniform, in that some epithelial acini had
large numbers of adjacent positive cells whereas others had relatively
few. To try and quantitate this phenomenon a simple point-counting
protocol was used to enumerate the number of cells staining positively
on FGF2 immunohistochemistry in periacinar and stromal areas. At x200
magnification, an ocular micrometer was aligned parallel to the base of
epithelial acini chosen at random and all positively staining cells
crossing the ocular micrometer were counted for a total of 10
measurements per slide. The same measurement was then performed with
the ocular micrometer placed in a stromal area without adjacent
epithelium. Six slides each from normal peripheral zone, normal
transition zone, and BPH tissues were evaluated in this manner without
knowledge of their origin. Results are shown in Figure 2
. For each type of tissue the number of
FGF2-positive cells was significantly higher in the periacinar area
(paired t-test, P < 0.04). In addition,
there was a trend for higher cell counts in the periacinar areas of the
normal transition zone and BPH tissues compared to the peripheral zone
tissue, although this difference is not statistically significant. We
could not identify any obvious association of these areas of increased
numbers of FGF2-positive cells with atrophy, metaplasia, or
inflammatory infiltrate.
|
|
Given that the FGF2-positive cells are more common closer to the
epithelial acini we wished to determine whether there was a paracrine
factor or factors secreted by epithelial cells that induced FGF2
production by prostatic stromal cells. Such paracrine factors could
play a role in normal growth if they are secreted into the stroma or
might be released into the surrounding tissue if the epithelium is
disrupted during inflammation. To determine whether such a factor(s) is
secreted in vitro we collected conditioned medium from
primary cultures of prostatic epithelial cells after 72 hours of
incubation. The collection medium contained insulin as the only added
growth factor to avoid the effect of epidermal growth factor and/or
FGFs, which are normally present in the epithelial media, on the
stromal cells. The eight different conditioned mediums were then added
at a 1:10 dilution to primary cultures of prostatic stromal cells in
RPMI 1640 containing insulin and cell extracts prepared after 48 hours
of treatment. The FGF2 content of the extracts was then determined by
ELISA. As can be seen in Figure 3
the
cell extracts from stromal cells treated with conditioned medium
contained 1.2- to 6.9-fold more FGF2 after 48 hours of treatment than
control cells, with a mean increase of 3.1-fold. To determine whether
the epithelial-conditioned media also were able to induce increased
levels of FGF2 in the stromal medium, the stromal cells were treated
with epithelial-conditioned medium and aliquots removed at intervals
from 4 to 96 hours in various experiments. Aliquots were then assayed
by ELISA for FGF2 content. The results of two such experiments are
shown in Figure 4
. The FGF2 content of
the stromal media was increased up to 14-fold by 24 hours after
treatment and then declined throughout the next 48 hours. We have found
a consistent increase in the FGF2 content of medium from the stromal
cells treated with epithelial-conditioned medium, but the exact
magnitude and kinetics of FGF2 accumulation were variable. The peak of
FGF2 accumulation was between 6 and 48 hours and the increase relative
to controls varied from 1.2- to 14-fold (mean, 8.8-fold). The reason
for this variability is unclear. To determine whether the increased
concentration of FGF2 in the cell extracts and conditioned medium was
because of an increase in cell number or increased production of FGF2
per cell, the number of prostatic stromal cells was determined after 5
days of incubation with or without treatment with diluted conditioned
medium. There was no significant difference in cell number between the
treated and untreated stromal cells (data not shown). To rule out the
possibility that the increased FGF2 in the stromal medium was because
of release of preformed FGF2 because of toxicity caused by the
epithelial conditioned medium, we evaluated the percentage of dead
cells in treated and untreated stromal cultures by trypan blue
exclusion. The percentage of cells taking up trypan blue was
essentially the same (0.4 to 0.8%) at all time points tested in
treated and untreated cells, so the conditioned medium was not toxic to
the stromal cells.
|
|
To try and determine the identity of the factor responsible for
the FGF2 accumulation we assayed the epithelial-conditioned medium for
a number of cytokines, because it has been shown that cytokines can
induce FGF2 expression.12,13
We have shown previously that
IL-1
is present in conditioned medium from prostatic epithelial
cells11
but did not find significant induction of FGF2
expression in prostatic stromal cells by this cytokine at
concentrations present in conditioned medium (data not shown). IL-6,
which is produced by prostatic epithelial cells in culture, also did
not significantly induce FGF2 accumulation at concentrations found in
the epithelial conditioned medium (data not shown). IL-8 was present at
an average concentration 2.4 ± 0.24 ng/ml (SEM, n
= 14) in the conditioned mediums from the prostatic epithelial cells.
Prostatic stromal cells also express detectable IL-8, but only at
approximately one-twentieth the level expressed by epithelial cells.
Using recombinant IL-8 at 167 pg/ml, approximately equivalent to the
concentration of IL-8 found in the diluted conditioned medium, we found
a threefold increase in FGF2 release by prostatic stromal cells by 24
hours after treatment (Figure 5)
, similar
to the level of induction by the conditioned medium. IL-8 also lead to
a similar increase in accumulation of intracellular FGF2 in treated
stromal cells (data not shown). We have tested the ability of IL-8 to
induce FGF2 expression in 10 different experiments and although the
exact magnitude of induction is somewhat variable there was induction
of FGF2 expression in all cases. To verify that the FGF2-inducing
activity of the conditioned medium was because of IL-8, we pretreated
the conditioned medium with anti-IL-8 neutralizing antibody. As can be
seen in Figure 6A
, this pretreatment
essentially eliminated the response of the stromal cells to the
conditioned medium. This experiment has been repeated four times with
similar results in all cases. Treatment with control antibody (anti-ß
actin) had no effect on FGF2 induction. LPS has been shown to
down-regulate IL-8 receptor by both transcriptional9
and
posttranscriptional9,10
mechanisms. When prostatic stromal
cells were pretreated with LPS before addition of the conditioned
medium, the FGF2-inducing activity was substantially reduced (Figure 6B)
, similar to the effect of such pretreatment on FGF2 induction by
recombinant IL-8. Finally, we noted that the degree of induction of
FGF2 in stromal cell extracts (as shown in Figure 3
) was proportional
to the IL-8 concentration in the conditioned medium, with a correlation
coefficient of 0.7 by linear regression for the six samples in which
both values were available (data not shown). Thus, IL-8 is the major
paracrine inducer of FGF2 production present in epithelial-conditioned
medium.
|
|
, there is substantial expression
of IL-8 by prostatic basal cells and weaker expression by the luminal
secretory cells. Expression was also detected in some stromal cells
with fibroblastic morphology. This is consistent with our observation
that prostatic stromal cells in culture secrete IL-8, although at a
much lower level than by cultured prostatic epithelial cells. As
expected, inflammatory cells also expressed detectable IL-8.
|
FGF2 protein levels have been shown to be controlled by
alterations in transcription,12-16
mRNA
stability,17
and protein translation18
in
different cell types. To determine whether IL-8 induced FGF2 mRNA in
prostatic stromal cells, such cells were treated with recombinant IL-8,
RNAs extracted, and Northern blotting performed using a FGF2 cDNA
probe. RNA bands of 
6.0, 4.2, and 3.1 kb were present, as has been
described in cardiac myocytes.19
As can be seen in Figure 8A, IL
-8 induced increased levels of FGF2
mRNA as early as 6 hours after treatment. By densitometry, after
normalization for variation in mRNA loading using control
glyceraldehyde-3'-phosphate dehydrogenase hybridization a sevenfold
increase in FGF2 mRNA levels was present at 6 hours, which decreased
slightly by 24 hours. This induction of FGF2 mRNA by IL-8 was confirmed
in three separate experiments (data not shown). This increase was also
confirmed by semiquantitative reverse transcriptase-polymerase chain
reaction. As can be seen in Figure 8B
, RNA from stromal cells treated
with IL-8 for 24 hours gave a visible band after 20 cycles of
polymerase chain reaction using FGF2-specific primers, whereas RNA from
untreated stromal cells did not give a visible band until 30 cycles of
amplification. Bands for the control ß2 microglobulin were equal in
treated and untreated cells. Epithelial-conditioned medium also induced
increased FGF2 mRNA levels by 2 hours after treatment (Figure 8C)
,
which by densitometry was approximately threefold. Thus the increase in
FGF protein induced by epithelial-conditioned medium in stromal cell
extracts is similar to the increase in FGF2 mRNA because of these
treatments.
|
Having established that IL-8 can act as an epithelial-derived paracrine inducer of FGF2 production by stromal cells in vitro we sought evidence that this paracrine stimulation might occur in vivo. We therefore assayed tissue extracts from normal transition zone and BPH tissue for IL-8 content by ELISA. The tissue content of IL-8 was quite variable, ranging from undetectable (<0.2 ng/g wet weight) to 128 ng/g wet weight. The mean IL-8 content of the normal transition zone was 16.4 ± 9.7 ng/g wet weight (SEM, n = 7) whereas BPH tissue contained 32.9 ± 7.7 ng/g (SEM, n = 16). The twofold higher IL-8 concentration in BPH tissue is the same as to the twofold higher level of FGF2 in BPH, consistent with a correlation between the expression of these two polypeptides. Thus IL-8 is expressed at biologically significant, but variable, levels in human prostate tissue in vivo, with higher levels present in BPH tissue.
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
We have found that FGF2-producing stromal cells tend to be located near epithelial acini in the prostate and that epithelial cells release IL-8, which can induce FGF2 production in vitro. In addition, IL-8 is present in relatively high quantities in prostate tissue in vivo. The correlation between increased IL-8 and FGF2 levels in BPH tissues in vivo is consistent with the idea that IL-8 may act in a similar paracrine manner in vivo. The FGF2 induced in stromal cells by IL-8 can act as an autocrine growth factor for prostatic stromal cells.4,6,7 FGF2 is also a growth factor for prostatic epithelial cells.5,6 Thus it is possible that a double paracrine loop can be established in which IL-8 is secreted by epithelial cells, which then induces FGF2 expression by stromal cells, which can then induce epithelial proliferation and further increases in IL-8 expression, which in turn leads to increased FGF2 expression and so forth. This double paracrine loop is functionally equivalent to an autocrine loop and can result in increased and poorly controlled proliferation. Although it is clear that many factors may control FGF2 levels in the prostate, our data suggests that IL-8 may be an important regulator of FGF2 expression in vivo, with important functional implications for the pathophysiology of BPH.
FGF2 mRNA levels are increased by treatment of prostatic stromal cells with IL-8 or epithelial-conditioned medium. A twofold increase in FGF2 mRNA in BPH tissues has been observed by Mori and colleagues,21 consistent with the idea that FGF2 expression is controlled primarily by the level of mRNA in vivo. FGF2 transcription is regulated by a variety of factors in different cell types14-16 including cytokines.12,13 Posttranscriptional regulation of FGF2 mRNA stability has also been described,17 so it is also possible that increased mRNA stability may account for the increased FGF2 mRNA levels after IL-8 or conditioned medium treatment of stromal cells. The fact that the increase in the level of FGF2 mRNA is similar to the increase in FGF2 protein argues that alterations in FGF2 translational efficiency are probably not critical in the increased expression of FGF2 protein in BPH.
Given the highly variable levels of IL-8 in the human prostate in vivo it is likely that control of IL-8 expression in the prostate is complex. We have shown that IL-8 is produced and secreted by prostatic epithelial cells in vitro and expressed by prostatic basal cells and to lesser extent luminal epithelial cells in vivo. As shown by immunohistochemistry of prostatic tissue using anti-IL-8 antibodies, inflammatory cells also contribute to IL-8 levels in vivo, consistent with the known role of inflammatory cells in IL-8 production.22 It is well known that normal prostate and BPH tissue often contain chronic inflammation, which can be extensive.23,24 However, we did not observe any obvious correlation between FGF2-expressing cells detected by immunohistochemistry and infiltrates of chronic inflammatory cells, so the extent to which inflammation contributes to IL-8 and FGF2 expression in vivo is unclear. In addition, we do not know the extent to which the IL-8 produced by the epithelial cells is normally released onto the stroma or whether inflammation and atrophy may increase such release.
The finding that FGF2-expressing stromal cells are increased near
epithelial acini and FGF2 can be induced by IL-8 released by prostatic
epithelial cells is similar to our previously reported results in which
FGF7-expressing stromal cells are increased adjacent to epithelial
cells and can be induced by IL-1, which is increased in BPH
tissues.11
FGF7 is an epithelial-specific growth factor
and its level of expression is strongly correlated with increased
epithelial proliferation in BPH.4
Thus the expression of
two different cytokines by prostatic epithelial cells seems to drive
the expression of important epithelial and stromal growth factors,
contributing to the abnormal proliferation in BPH. This raises the
question of whether there may be a common underlying mechanism inducing
the production of these cytokines in vivo that may
contribute to the pathogenesis of BPH.
IL-8 has been demonstrated to be expressed by prostate cancer cells by immunohistochemistry.25 In addition, the PC-3 prostate cancer cell line expresses IL-826,27 and inhibition of IL-8 activity decreases tumorigenicity26,27 and metastasis27 of PC-3 cells in vivo in SCID or nude mouse model systems. In agreement with these observations, direct analysis of 17 prostate cancer tissue extracts in our laboratory has shown that IL-8 is substantially increased in prostate cancer tissues (60.1 ng/g wet wet, unpublished observations). IL-8 is an angiogenic factor and part of its biological activity in promoting tumor progression is almost certainly because of its direct effect on endothelial cell proliferation and angiogenesis. However, we have shown previously that FGF2 is increased threefold in primary prostate cancer tissues, is expressed in the cancer stromal cells, and can act as a growth factor for prostatic epithelial cells. It is likely that the increased IL-8 expression by the cancer cells induces increased FGF2 production by adjacent stromal cells, which can then act a paracrine growth factor for the cancer cells, and in this manner contribute to prostate cancer progression.
In this report we have demonstrated that FGF2-expressing stromal cells tend to be located near epithelial acini and that epithelial cells can release IL-8, which can induce FGF2 expression. This finding has important implications for the pathophysiology of BPH and for prostate cancer progression. Further investigations are needed to understand the reason for increased IL-8 expression in BPH and cancer, with the goal of disrupting this abnormal expression to treat these two common diseases of older men.
|
Acknowledgements |
|---|
|
Footnotes |
|---|
Supported by National Institutes of Health grant R01 DK54170.
Accepted for publication April 11, 2001.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
This article has been cited by other articles:
 |
|
 |
|
  G. Penna, B. Fibbi, S. Amuchastegui, C. Cossetti, F. Aquilano, G. Laverny, M. Gacci, C. Crescioli, M. Maggi, and L. Adorini Human Benign Prostatic Hyperplasia Stromal Cells As Inducers and Targets of Chronic Immuno-Mediated Inflammation J. Immunol., April 1, 2009; 182(7): 4056 - 4064. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Cai, J. Wang, R. Li, G. Ayala, M. Ittmann, and M. Liu GGAP2/PIKE-A Directly Activates Both the Akt and Nuclear Factor-{kappa}B Pathways and Promotes Prostate Cancer Progression Cancer Res., February 1, 2009; 69(3): 819 - 827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Ayala, J. Yan, R. Li, Y. Ding, T. C. Thompson, M. P. Mims, T. G. Hayes, V. MacDonnell, R. G. Lynch, A. Frolov, et al. Bortezomib-Mediated Inhibition of Steroid Receptor Coactivator-3 Degradation Leads to Activated Akt Clin. Cancer Res., November 15, 2008; 14(22): 7511 - 7518. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B Kwabi-Addo, M Ozen, and M Ittmann The role of fibroblast growth factors and their receptors in prostate cancer Endocr. Relat. Cancer, December 1, 2004; 11(4): 709 - 724. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. G. Vaday, S.-B. Hua, D. M. Peehl, M. H. Pauling, Y.-H. Lin, L. Zhu, D. M. Lawrence, H. D. Foda, and S. Zucker CXCR4 and CXCL12 (SDF-1) in Prostate Cancer: Inhibitory Effects of Human Single Chain Fv Antibodies Clin. Cancer Res., August 15, 2004; 10(16): 5630 - 5639. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
